Inhaled Corticosteroid/Long-Acting beta(2)-Agonist Combination Therapy for Asthma: Attitudes of Specialists in Europe
Background: As new combinations of inhaled corticosteroids (ICSs) and long-acting beta(2)-agonists (LABAs) become available for the treatment of asthma, it will be important to determine criteria against which they can be evaluated. The aim of this study was to assess which attributes of combination therapy physicians consider most important. Methods: Primary and secondary care asthma specialists